Comparative Pharmacology
Head-to-head clinical analysis: ARAKODA versus PYRIMETHAMINE SULFADOXINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAKODA versus PYRIMETHAMINE SULFADOXINE.
ARAKODA vs Pyrimethamine-Sulfadoxine
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.
Pyrimethamine inhibits dihydrofolate reductase, blocking tetrahydrofolate synthesis. Sulfadoxine inhibits dihydropteroate synthase, blocking folate synthesis. Sequential blockade of folate metabolism.
400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).
Pyrimethamine 25 mg plus sulfadoxine 500 mg per tablet; typical adult dose for acute uncomplicated malaria is 3 tablets (pyrimethamine 75 mg, sulfadoxine 1500 mg) orally as a single dose. For toxoplasmosis in immunocompromised patients: loading dose pyrimethamine 200 mg orally once, then pyrimethamine 50-75 mg orally once daily plus sulfadoxine 1000-1500 mg orally once daily (dosing based on sulfadoxine component) for 4-6 weeks, then reduce to half.
None Documented
None Documented
Terminal elimination half-life: approximately 14-16 days (range 12-19 days) in healthy adults; this long half-life is due to extensive tissue distribution and slow release from tissues, providing prophylactic coverage for up to 4 weeks after a single dose.
Pyrimethamine: ~80-120 hours; Sulfadoxine: ~100-200 hours. Long half-lives allow single-dose therapy for malaria.
Biliary/fecal: ~90% unchanged; renal: <1% unchanged (dose-proportional urinary excretion of tafenoquine is minimal, with most eliminated via feces as unchanged drug and minor metabolites).
Renal: ~60% unchanged sulfadoxine, ~5% unchanged pyrimethamine; fecal: ~10% pyrimethamine. Biliary excretion minimal.
Category C
Category C
Antimalarial
Antimalarial